Bizarre Patents
Apparatus for Simulating a High Five
A self-righting hand-arm configuration which is adapted to pivot when struck by a user, thereby simulating a "high five."
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8067012 | Treatment of melanoma using HSV mutant Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the γ34.5 gene in the long repeat region (RL) such that the γ34.5 gene is a non-functional, manufacture of medicaments and methods of testi... | 11/29/2011 |
| 7824690 | Marek's disease virus vaccine An effective vaccine for Marek's disease may be prepared using a viral agent which is a Marek's disease virus unable to express a functional meq protein. This viral agent is effective to elicit an immune response in a chicken to very virulent strains of Marek's dise... | 11/02/2010 |
| 7674468 | Treatment of cancer using HSV mutant Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the γ34.5 gene in the long repeat region (RL) such that the γ34.5 gene is a non-functional, manufacture of medicaments and methods of testi... | 03/09/2010 |
| 7524508 | Subgenomic replicons of the flavivirus dengue The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection. ... | 04/28/2009 |
| 7431931 | Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions The present invention provides compositions for making a medicament and methods for the administration of a vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human x rhesus reassortant rotavirus compositions were... | 10/07/2008 |
| 7416732 | Papilloma virus-like particles, fusion proteins as well as processes for their production The invention relates to the recombinant production of proteins as well as VLPs which are suitable as a vaccine for therapeutic and prophylactic vaccination. The invention also relates to processes for the production and purification of recombinant papilloma virus p... | 08/26/2008 |
| 7384643 | Recombinant poxvirus Use for novel chemokine-binding protein designated A41L, and chemokine-binding fragments thereof, for the treatment of conditions such as inflammation. The A41L protein binds to chemokines in the CXC group. ... | 06/10/2008 |
| 7344722 | Cold-adapted influenza virus The cold-adapted master strain A/Ann Arbor/6/60 7PI (H2N2) and progenitor wild type E2(3) viral strains have been deposited and their genomic sequences identified. Seven nucleotide differences were found between the sequences identified herein and the previously pub... | 03/18/2008 |
| 7335363 | Membrane virus host range mutations and their uses as vaccine substrates The present invention is directed to genetically engineered, membrane-enveloped viruses with deletion mutations in the protein transmembrane domains. Also provided are viral vaccines based on the engineered viruses, methods of producing and using such vaccines. ... | 02/26/2008 |
| 7332170 | Classical swine fever virus virulence determinant and a novel classical swine fever vaccine Transposon linker insertion mutagenesis of a full-length infectious clone of the highly pathogenic classical swine fever virus (CSFV) isolate Brescia (pBIC) was used to identify genetic determinants of CSFV virulence and host range. A virus mutant, RB-C22 (RB-C22v),... | 02/19/2008 |
| 7316813 | Influenza vaccine composition An inactivated influenza virus preparation is described which comprises a haemagglutinin antigen stabilized in the absence of thiomersal, or at low levels of thiomersal, wherein the haemagglutinin is detectable by a SRD assay. The influenza virus preparation may com... | 01/08/2008 |
| 7314919 | Human recombinant antibody against the hepatitis C (HCV) non structural NS3 protein nucleic acid and uses thereof An human antibody anti-NS3 protein of the hepatitis C virus (HCV) is described, as will as synthetic and recombinant fragments thereof able to inhibit the helicase activity of the NS3 protein, both in vitro and in vivo, and uses thereof. ... | 01/01/2008 |
| 7311918 | Rotavirus subunit vaccine The present invention is directed to the generation and use of recombinant rotavirus fusion proteins as immunogens to produce a protective immune response from immunized individuals. In one embodiment, the present invention contemplates a recombinant rotavirus fusio... | 12/25/2007 |
| 7303754 | MVA expressing modified HIV envelope, gag, and pol genes The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes. ... | 12/04/2007 |
| 7294500 | Mosaic infectious bursal disease virus vaccines The invention relates to Infectious Bursal Disease Virus (“IBDV”) and vaccines therefor. Provided are infectious recombinant Infectious Bursal Disease Virus (“rIBDV”) essentially incapable of growing in a cell that is not derived from a bursa cell, or an inf... | 11/13/2007 |
| 7285280 | Vaccine The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly ... | 10/23/2007 |
| 7273617 | Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof Infectious cDNA clones of North American Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) are provided. Further provided are cDNA clones comprising genetic mutations. Also provided are vaccines comprising cDNAs, including genetically and immunologically m... | 09/25/2007 |
| 7267815 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Altern... | 09/11/2007 |
| 7262045 | Methods of producing influenza vaccine compositions Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided. ... | 08/28/2007 |
| 7250171 | Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome modified to encode a chimeric glycoprotein incorporating one or more heterologous antigenic domains, fragments, or epitopes of a second, antigenically distinct HPIV... | 07/31/2007 |
| 7244434 | Replicons of pestviruses that do not express C and or E1 protein and infectious viral particles containing same, that can be used in vaccines The present invention provides new Pestiviral RNA genomes (replicons) that are able to replicate, and can be packaged into infectious viral particles in cells that complement the missing protein(s), but do not produce infectious progeny virus. Such replicons can be ... | 07/17/2007 |
| 7229625 | Retrovirus-like particles made non-infectious by a plurality of mutations Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product, eliminate integrase activity of the pol gene product and eliminate RNase H ac... | 06/12/2007 |
| 7229624 | Ordered molecular presentation of antigens, method of preparation and use The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatme... | 06/12/2007 |
| 7223409 | DNA-based vaccine against the encephalitis alphaviruses This invention relates to the development of a mammalian expression vector, under which expression of the structural genes of western equine encephalitis virus have been placed under the control of an eucaryotic promoter. When the recombinant vector is administered ... | 05/29/2007 |
| 7223411 | Herpesvirus replication defective mutants A herpesvirus vaccine comprising a mutated herpesvirus suspended in a pharmaceutically acceptable carrier. The mutated herpesvirus is capable of infecting cells of the mammal to be vaccinated, but incapable of completing a replicative cycle, and it is capable of eli... | 05/29/2007 |
| 7205013 | Recombinant RSV virus expression systems and vaccines The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant ... | 04/17/2007 |
| 7201911 | Cloned genomes of infectious hepatitis C viruses and uses thereof The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the developme... | 04/10/2007 |
| 7198934 | Recombinant MVA virus, and the use thereof The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use... | 04/03/2007 |
| 7182947 | Papillomavirus truncated L1 protein and fusion protein constructs Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed. ... | 02/27/2007 |
| 7179473 | Attenuated pestiviruses This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein ERNS is inactivated, methods of preparing, using and detecting these. ... | 02/20/2007 |
| 7132106 | Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encode... | 11/07/2006 |
| 7128915 | Membrane virus host range mutations and their uses as vaccine substrates The present invention is directed to genetically engineered, membrane-enveloped viruses with deletion mutations in the protein transmembrane domains. Also provided are viral vaccines based on the engineered viruses, methods of producing and using such vaccines. ... | 10/31/2006 |
| 7108855 | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recom... | 09/19/2006 |
| 7101685 | Recombinant Sendai virus A method for generating Sendai virus particles by transfecting the Sendai virus genome to a host expressing all genes for the initial viral replication has been developed, enabling the genetic manipulation of Sendai virus and effective utilization of said virus as t... | 09/05/2006 |
| 7101554 | Picornaviruses, vaccines and diagnostic kits A new group of picornaviruses is disclosed. The picornaviruses of the invention comprise in the non-coding region of their viral genome a nucleotide sequence which corresponds to cDNA sequence (I) or homologous sequences having at least 75% homology to the SEQ ID NO... | 09/05/2006 |
| 7094411 | Avirulent, immunogenic flavivirus chimeras Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the ... | 08/22/2006 |
| 7074410 | Modified HCV peptide vaccines Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, a... | 07/11/2006 |
| 7063835 | Virus strains The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains. ... | 06/20/2006 |
| 7063851 | Herpes viruses for immune modulation A method of stimulating an immune response in a human or animal subject, which method comprises administering to a subject in need thereof an effective amount of an attenuated herpes virus which: (i) lacks a functional vhs gene, or... | 06/20/2006 |
| 7045335 | Alphavirus replicon vector systems The present invention provides compositions useful in and methods for producing populations of infectious, replication-defective alphavirus replicon particles that contain no replication-competent alphavirus particles, as determined by passage on cells in culture. T... | 05/16/2006 |
